PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Kakkar, Ajay K.
TI  - Use of Dalteparin beyond 6 Months in Cancer Patients with VTE is Feasible
DP  - 2013 Sep 01
TA  - MD Conference Express
PG  - 13--14
VI  - 13
IP  - 13
4099  - http://mdc.sagepub.com/content/13/13/13.short
4100  - http://mdc.sagepub.com/content/13/13/13.full
AB  - Although the guidelines for treating venous thromboembolism (VTE) in cancer patients recommend anticoagulation with low-molecular-weight heparin for at least 3 to 6 months, or for the duration of the malignancy, uncertainty exists concerning whether to extend anticoagulation longer to prevent recurrence of VTE. The objective of the Evaluation of Dalteparin for Long-Term (One Year) Treatment of Blood Clots in Subjects With Cancer study [DALTECAN; NCT00942968] was to assess the consequences of extending anticoagulation with dalteparin beyond 6 months in cancer-associated VTE.